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Fibroblast growth factor (FGF) has been purified to homogeneity from human brain by a procedure involv- 
ing salt precipitation, cation-exchange chromatography. Heparin-Sepharose affinity chromatography and 
reverse-phase HPLC. Isolation was monitored by radioimmu~oassay and/or by testing column fractions 
for their capacity to stimulate the proliferation of vascular endothelial cells in vitro. The amino-terminal 
sequence of human brain FGF was, determined as Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe- 
Pro-. This sequence is identical to that of the amino-terminal region of bovine FGF. Additional evidence, 
including amino acid composition, chromatographic retention behavior, and immunoreactivity suggest hat 
the human and bovine mitogens are very similar in structure. 
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1. INTRODUCTION 
Fibroblast growth factor (FGF) has been 
isolated from bovine pituitary tissue and shown to 
be a basic polypeptide (PI 9.4) with an approx- 
imate molecular mass of 16 kDa that possesses the 
amino-terminal sequence Pro-Ala-Leu-Pro-Glu- 
Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly [ 1-3 J . 
A mitogen indistinguishable from pituitary FGF 
has also been isolated from bovine brain tissue [3]. 
FGF is mitogenic for a variety of neuroectoderm- 
and mesoderm-derived cell types [2,4-61 and is 
angiogenic in vivo [2,7]. Owing to the novel and 
highly effective Heparin-Sepharose affinity 
chromatography procedure for the purification of 
FGF-like growth factors described by Shing et al. 
[8] the isolation of pure FGF from brain (31 and 
other tissues of bovine origin (in preparation) and 
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the partial chemical characterization of these 
mitogens has been achieved using relatively small 
quantities of tissue. We now report the purifica- 
tion to homogeneity of two forms of basic FGF 
from human brain and show that they are struc- 
turally closely related to basic FGF from bovine 
pituitary or brain. 
2. MATERIALS AND METHODS 
2.1. Brain tissue 
Brains (24-48 h post-mortem) were provided by 
Dr X. Trujillo, UCSD Medical School, San 
Diego). Tissue was stored at -80°C until used. 
2.2. Isolation of FGF 
For the preparation of partially purified FGF a 
previously published procedure was used [3,9]. 
Briefly, brain tissue (2.3 kg) was extracted in 
0.15 M ammonium sulfate at pH 4.5. The major 
mitogenic activity was enriched by ammonium 
Published by Elsevier Science Publishers B. V. (Biomedical Dwrsron) 
00145793/85/$3.30 0 1985 Federation of European Biochemical Societies 177 
Volume 185, number 1 FEBS LETTERS June 1985 
sulfate precipitation and by batch adsorption/elu- 
tion using a Carboxymethyl-Sephadex C-50 (Phar- 
macia) cation-exchange column (3 x 20 cm). 
~jtogenic activity eluting in the 0.6 M sodium 
chloride fraction was further purified by Heparin- 
Sepharose (Pharmacia) affinity chromatography 
at room temperature using a linear salt gradient for 
elution. Fractions with biological activity were 
subjected to final purification in two reverse-phase 
HPLC systems. Further details are contained in 
the figure legends. 
2.3. Assays 
Column fractions were either tested for their 
ability to stimulate the proliferation of adult 
bovine aortic arch endothehal (ABAE) cells as in 
[2,3] and/or by radioimmunoassay (RIA). The 
RIA was developed [l,lO] by raising antibodies 
against the synthetic peptide TyrlO-FGF(l-9) the 
sequence of which corresponds to that of the first 
9 residues of bovine FGF. Additional details are 
indicated in the figure legends. 
2.4. Structural characterization 
Amino acid analyses were performed on a Li- 
quimat III anaIyzer (Kontron, Zurich) as in [I 11. 
Amino acid sequence analysis of the unmodified 
HPLC-purified growth factor was carried out us- 
ing the Applied Biosystems gas/liquid phase 
microsequenator 1121. Phenylthiohydantoin 
derivatives of amino acids were analyzed by HPLC 
1131. 
3. RESULTS AND DISCUSSION 
The purification to homogeneity of human brain 
FGF is shown in fig. 1. Heparin-Sepharose affinity 
chromatography yielded a highly purified protein 
fraction eluting at 1.55 1.6 M N&l that contained 
the majority of the immunoreactivity. Further 
purification by reverse-phase HPLC revealed the 
presence of multiple forms of FGF (fig.lB) of 
which two immunoreactive (not shown) and bioac- 
tive forms {both derived from the major protein 
peak shown in fig.lB) were isolated (fig.lC) and 
shown to be pure by sequence analysis (see below). 
As determined by amino acid analysis, only 
200-300 pmol pure mitogens were isolated from 
2.3 kg brain tissue. This in contrast with the con- 
siderably larger amounts of FGF that can be ob- 
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Fig.1. Isolation of human brain FGF. (A) Heparin- 
Sepharose affinity chromatography. The active fraction 
from Carboxymethyl-Sephadex C-SO (I 10 ml) was 
directly loaded onto a Heparin-Sepharose column (1.6 x 
5 cm) that had been equilibrated with 0.6 M sodium 
chloride in 0.01 M ‘Iris-Cl (pH 7.0). The column was 
first washed with the same buffer (flow rate 90 ml/h) 
until the absorbance at 280 nm returned to the baseline 
value and then with 1.i M sodium chloride in 0.01 M 
Tris-CI (pH 7). Mitogenic activity was eluted with a 
60-min linear salt gradient of 1.1 M to 2.0 M sodium 
chloride in 10 mM Tris-Cl (pH 7). The flow rate was 
1.5 ml/min, fractions of 1.5 ml were collected. Aliquots 
of 2Ok1 of each fraction were used for RIA. ir-FGF, 
immunoreactive FGF. The btack horizontal bar under 
the chromatogram indicates fractions used for further 
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tained from similar quantities of bovine brain [3]. 
It is conceivable that the lower yields of human 
mitogen are a result of post-mortem degradation 
of FGF in human tissue. Amino acid compositions 
of the two isolated FGFs (fig.lC) are shown in 
table 1. Both the quantitatively major (peak 11) 
and minor (peak I) forms possess amino acid com- 
positions that are virtually indistinguishable and 
are also very similar to the composition of bovine 
FGF [l]. Amino-terminal sequences of the human 
FGFs are given in table 2. Although some amino 
acid residues could not be identified unequivocally 
due to low amounts of proteins sequenced, the 
data nevertheless how clearly that the amino- 
terminal sequences of the two human FGF forms 
are identical. The sequences are also identical to 
that of bovine brain (table 2) and pituitary FGF 
Ill. The sequencing data for bovine FGF are in- 
cluded in table 2 because they have not been 
previously published. For the sequence analysis we 
used a preparation of bovine brain FGF, the 
purification. (B) Reverse-phase HPLC of immuno- 
reactive Heparin-Sepharose fractions on a Vydac C4 
column (25 x 0.46 cm, 300 A pore size, 5 pm particle 
size, the Separations Group, Hesperia, CA). The sample 
(18 ml) was loaded by pumping it directly onto the 
column. FGF-like material was eluted with a 90-min 
gradient of n-propanol (iO-16vo) in 30 mM phosphoric 
acid. After completion of the gradient the column was 
washed with 30 mM phosphoric acid in n-propanol. The 
flow rate was 0.6 ml/min, fractions of 1.8 ml were 
collected; 20-,uI aliquots of each fraction were used for 
RIA. For bioassay lo-p1 aliquots were diluted T-fold in 
Dulbecco’s modified Eagle’s medium containing 0.5% 
bovine serum albumin, and IO-pi portions were added to 
ABAE cell cultures seeded at an initial density of 20000 
cells/35 mm dish. Addition of diluted column fractions 
to cell cultures was repeated after 48 h and cells were 
counted after 4 days. Densities of control cultures were 
1.5 x lo5 cells/dish after 4 days. The black horizontal 
bar under the chromatogram denotes the fraction used 
for final purification. (C) Reverse-phase HPLC of the 
major bioactive FGF fraction from the first HPLC 
purification step (fig. IB). A Vydac C4 column was used 
in conjunction with an acetonitrile gradient (28-34% in 
90 min) in 0.1% (v/v) trifluoroacetic acid as the mobile 
phase. Flow rate, 0.6 mI/min. Fractions were collected 
manually as appropriate for the separation of the two 
peaks. Aliquots of column fractions (1 pl per lOO,tri 
fraction volume) were used for bioassay as described in 
(B). 
Table 1 
Amino acid compositions of HPLC-purified human 
brain FGFs” 
Amino 
acid 
Residues/moleculeb 
Peak I Peak II Bovine 
pituitary FGFC 
Asx 12.7 11.5 10 
Thr 5.0 5.4 4 
Ser 9.6 9.1 9 
Glx 12.4 13.1 12 
Pro 9.0 8.5 9 
Gly 16.6 15.0 16 
Ala 9.1 9.1 9 
cys 5.3 6.2 6 
Val 4.5 5.1 5 
Met 1.9 1.7 2 
Be 3.2 3.9 3 
Leu 12.7 13.0 I1 
Tyr 5.9 5.4 7 
Phe 6.5 6.6 7 
His 2.6 2.3 3 
LYS 11.6 11.7 13 
Trp 0.3 0.4 1 
Arg 9.7 10.3 II 
a Values are means from 2-3 determinations (18 h 
hydrolyses at 110°C) using 5 pmol protein per 
analysis. Results are not corrected for hydrolysis- 
related losses 
b Compositions are based on 140 amino acid residues per 
molecule 
’ From [l] 
purification of which by Heparin-Sepharose affini- 
ty chromatography and reverse-phase HPLC was 
described in ]3]. The conclusion that various forms 
of human and bovine FGFs have identical amino- 
terminal sequences i  also corroborated by the fact 
that these mitogens crossreact (parallel displace- 
ment curves in the RIA) with antibodies specifical- 
ly recognizing the amino-terminal sequence of 
bovine pituitary FGF [I ,101. 
The combined evidence (amino-terminal se- 
quence, amino acid composition, chromatographic 
retention behavior, immunoreactivity, bioactivity) 
strongly suggests that human brain FGF is struc- 
turaily closely related to bovine brain or pituitary 
basic FGF. Although molecular mass and isoelec- 
tric point of human brain FGF have not been 
determined due to the small quantities of mitogen 
179 
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Table 2 
Amino-terminal sequences of two forms of human brain 
FGF and the major form of bovine brain FGF 
Cycle Human brain FGF Bovine brain 
FGF 
Peak I Peak II 
PTH- pmol PTH- pmol PTH- pmol 
AA” AA AA 
1 Pro 405 
2 Ala 118 
3 Leu 177 
4 Pro 165 
5 Glu 77 
6 Asp 67 
7 GLY 106 
8 Gly 26 
9 Ser 22 
10 Gly 39 
11 Ala 27 
12 Phe 33 
13 Pro 91 
14 b _ 
15 Gly 25 
pm01 
sequenced ’ 
Initial yield 
(070) L 
Repetitive yield 
(Q) 79.6 
b 
Ala 
Leu 
Pro 
Gen 
Asp 
GLY 
Gly 
Ser 
_ 
_ 
_ 
_ 
_ 
150 
30 
_ 
14 
38 
67 
22 
14 
39 
12 
4 
_ 
_ 
_ 
_ 
Pro 38 
Ala 31 
Leu 27 
Pro 24 
Glu 13 
Asp 4.2 
Gly 17 
Gly 3.0 
Ser 2.0 
b _ 
Ala 12 
Phe 8.0 
Pro 6.2 
Pro 4.7 
Gly 7.7 
16 
86.7 88.9 
a PTH-AA, phenylthiohydantoin amino acid 
b PTH-AA identification uncertain 
’ Values obtained are unreliable 
Analysis of phenylthiohydantoin amino acids showed no 
evidence for > 10% protein contamination of samples 
available, it is reasonable to assume, based on the 
amino acid compositions, that human and bovine 
FGFs are also closely related with respect to size 
and isoelectric point. 
Heparin-Sepharose affinity chromatography is a 
powerful technique for the isolation of pituitary 
and brain FGFs. We have previously shown that 
this purification step can afford a 3000-4000-fold 
enrichment of the mitogen, yielding essentially 
pure bovine pituitary FGF [3], as well as highly 
purified bovine or human brain FGF preparations, 
the heterogeneity of which can be ascribed for the 
most part to the presence of multiple molecular 
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forms of the same mitogen ([3], fig.lB,C of this 
report). Interestingly, Heparin-Sepharose also 
displays affinity for brain-derived acidic mitogens 
(pZ 5-6) for endothelial cells. Using Heparin- 
Sepharose affinity chromatography, Conn and 
Hatcher [14] purified two endothelial cell growth 
factors (pZ = 5.2) from human brain, Maciag et al. 
[15] purified an endothelial cell mitogen, with 
similar pZ (5.5) and molecular mass, from bovine 
brain, and most recently, Klagsbrun and Shing [ 161 
demonstrated the presence in bovine brain and 
hypothalamus of both acidic and basic growth fac- 
tors for capillary endothelial cells. Based on 
available evidence it may reasonably be assumed 
that the basic mitogen of Klagsbrun and Shing is 
identical to basic FGF as reported by us [l-3]. 
Furthermore, it is conceivable that the above- 
mentioned acidic endothelial cell growth factors 
are structurally related to each other. The possibili- 
ty even exists that those mitogens are related to 
bovine brain acidic FGF isolated and partially 
characterized by Thomas et al. [17]. In this context 
it is most intriguing to speculate that other 
mitogens, previously described to occur in many 
tissues and characterized with various bioassays 
(e.g., chondrosarcoma-derived growth factor [8], 
cartilage-derived growth factor [ 181, retina-derived 
growth factor [19], eye-derived growth factor 
[20]), are structurally related to either basic or 
acidic FGF. Evidence is already available that at 
least basic FGF does occur in many tissues, e.g., 
macrophages [2 I], placenta [22], adrenals, corpus 
luteum, kidney (in preparation). However, definite 
conclusions will only be possible once the primary 
structures of these growth factors are known. 
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